Access levels
See the ECCO'21 access levels in the table below:
| Section of homepage/Programme element | Scientific Registration | Educational Registration | Exhibitor Registration |
|---|---|---|---|
| Opening page of Virtual Congress Platform (simple ECCO account holders not, only congress registered delegates!) |
yes | yes | yes |
| Programme (searchable programme, to browse through) |
yes | yes | yes |
| Scientific Programme | yes | no | no |
| Educational Programme | no | yes | no |
| Scientific Satellite Symposia | yes | yes | yes |
| Educational Satellite Symposia (everybody with an educational course registration, not only with registration for that specific course) |
no | yes | yes |
| Satellite Symposia Overview page (listing the Satellite Symposia) |
yes | yes | yes |
| Industry Exhibition | yes | yes | yes |
| e-Posters | yes | yes | yes |
| Media Library (incl. Abstract Book and JCC) |
yes | yes | yes |
| ECCO Booth | yes | yes | yes |
| Networking | yes | yes | yes |
| Help Desk | yes | yes | yes |
Satellite Symposia access for Prescribers only
| Satellite Symposium 1a - AbbVie: Leaping into the future: exploring IL-23 inhibition for CD management |
| Satellite Symposium 2a - Takeda: Targeting progression of Crohn’s disease to improve patient outcomes |
| Satellite Symposium 2c - Eli Lilly: Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed |
| Satellite Symposium 3a - Takeda: Breaking the vicious cycle of Crohn’s perianal fistulas – a multidisciplinary team approach |
| Satellite Symposium 3b - AbbVie: Leaping into the future: exploring IL-23 inhibition for CD management |
| Lunch Satellite Symposium LS1 - AbbVie: Next Generation Inhibition of JAK Signalling: Aspiring for New Depths in UC Outcomes |
| Satellite Symposium 4a - Takeda: Pushing the boundaries in the management of Ulcerative Colitis: Is “disease clearance” possible? |
| Lunch Satellite Symposium LS5 - AbbVie: Next Generation Inhibition of JAK Signalling: Aspiring for New Depths in UC Outcomes |
| Lunch Satellite Symposium LS6 - Takeda: IBD in COVID 19 pandemic times: Emerging evidence from clinical practice |